Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings.
●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process.
●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities.
●
Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related
— more than breast, prostate, lung, and colon cancers combined.
●
22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily
from this serious form of skin cancer.
●The partnership is expected to increase patient visits on Rocket Doctor's platform, improving access to care and continuity for at-risk individuals.
Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) —
Treatment.com
AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country.
Melanoma Canada's Mole Mobile units, Canada's first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform.
'Too many Canadians are going without the care they need simply because they don't have a family doctor,' said Dr. William Cherniak, Founder and CEO of Rocket Doctor. 'By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.'
Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor's intake system, enabling efficient, streamlined review and timely access to appropriate care.
The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it.
'With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,' said Falyn Katz, CEO of Melanoma Canada. 'Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don't have a family doctor, can seamlessly transition from screening to care. It's a powerful step forward in improving outcomes for patients who might otherwise be left waiting.'
The initiative is expected to increase patient traffic across Rocket Doctor's platform during Mole Mobile's national tour, while reinforcing Rocket Doctor's mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor's logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days' written notice of termination prior to the renewal date.
Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025.
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like.
Visit
www.rocketdoctor.ca
or contact
media@rocketdoctor.io
.
About Melanoma Canada
Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada's first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers.
Learn more at
www.melanomanetwork.ca
.
About
Treatment.com
AI Inc.
Treatment.com
AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally,
Treatment.com
AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support.
Treatment.com
AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at
www.treatment.com
or contact
info@treatment.com
.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
Email:
ehamza@treatment.com
Media inquiries:
media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on
Treatment.com
AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although
Treatment.com
believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and
Treatment.com
undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 minutes ago
- Business Wire
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of Meghan Geary as the Company's Senior Vice President of Operations, effective immediately. With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory. "I'm excited to join MedX at such a pivotal stage of its journey," said Geary. "Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success." The Company's CEO, John Gevisser added: 'Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.' About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration ('FDA'), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: https// This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Yahoo
3 hours ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Dr. Ritesh Kalra Scholarship to Support Aspiring Medical Professionals
Dr. Ritesh Kalra Scholarship SECAUCUS, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- The Dr. Ritesh Kalra Scholarship for Medical Students is now accepting applications for its 2026 award cycle, offering a $1,000 prize to a deserving undergraduate student on the path to becoming a doctor. Established by acclaimed physician Dr. Ritesh Kalra, this initiative seeks to encourage academic excellence, foster a spirit of compassion in medicine, and provide financial assistance to future healthcare leaders. The scholarship will be awarded through an engaging essay contest, providing applicants with an opportunity to share their vision for the future of medicine. Students are invited to reflect on the balance between technological advancements in healthcare and the human connection that remains at the heart of patient care. The award is open to undergraduate students in accredited institutions who are committed to pursuing a medical career. 'This scholarship represents more than financial assistance—it's a way to inspire the next generation of physicians to uphold both innovation and empathy in their work,' said Dr. Kalra. 'Medicine is not only a science; it's a calling that requires skill, dedication, and a genuine desire to help others.' About Dr. Ritesh Kalra Dr. Ritesh Kalra is a highly respected internal medicine specialist with decades of service in both private practice and hospital settings. His career spans extensive clinical work, award-winning research, and mentorship of medical students. Trained across prestigious institutions in Poland, New York, and Georgia, Dr. Ritesh Kalra has earned repeated recognition as a Top Doctor in Internal Medicine from 2020 through 2025. Fluent in Hindi and Punjabi, he connects with a diverse patient population and has devoted his career to improving healthcare delivery and patient outcomes. His inspiration for creating the scholarship stems from his belief in the power of education and the critical role that young, motivated doctors will play in the future of global health. Application Details The Dr. Ritesh Kalra Scholarship for Medical Students is open to all undergraduate students enrolled in accredited U.S. institutions who are on an academic track toward becoming a physician. Applicants must submit a 750–1,000-word original essay responding to the following prompt: "In the rapidly evolving field of medicine, how can future doctors balance technological advancement with the human connection that lies at the heart of patient care? Share your thoughts, supported by personal experiences, observations, or aspirations." Submissions should demonstrate critical thinking, originality, and a strong personal commitment to the medical field. Important Dates Application Deadline: May 15, 2026 Winner Announcement: June 15, 2026 The winning essay will be selected by the scholarship review committee based on insight, clarity, creativity, and the ability to convey a compelling vision for the future of healthcare. The $1,000 award will be sent directly to the recipient to support their educational expenses. How to Apply Applicants should send their essay along with their full name, contact information, school name, and field of study to apply@ The subject line should read: Dr. Ritesh Kalra Scholarship Application. The scholarship reflects Dr. Ritesh Kalra's ongoing mission to support the academic journeys of aspiring doctors and to encourage them to integrate technological expertise with compassionate care. Through this program, he hopes to inspire students to pursue medicine not only as a career but as a lifelong service to humanity. Contact InformationSpokesperson: Dr. Ritesh KalraOrganization: Dr. Ritesh Kalra Scholarship for Medical StudentsWebsite: apply@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
